Must-See Earnings Estimates for: NASDAQ:DMAC, NASDAQ:BCYC, NASDAQ:ALOT, ASX:BDR

0
75

DIAMEDICA THERAPEUTICS (NASDAQ:DMAC) EARNINGS INFORMATION (NASDAQ:DMAC)

DiaMedica Therapeutics last released its earnings data on March 11th, 2021. The reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.06. DiaMedica Therapeutics has generated $0.00 earnings per share over the last year. DiaMedica Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, May 12th, 2021 based off prior year’s report dates.

IS DIAMEDICA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:DMAC)

5 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for DiaMedica Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” DiaMedica Therapeutics stock.
DiaMedica Therapeutics

BICYCLE THERAPEUTICS (NASDAQ:BCYC) EARNINGS INFORMATION (NASDAQ:BCYC)

Bicycle Therapeutics last posted its quarterly earnings results on March 10th, 2021. The reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.36. Bicycle Therapeutics has generated ($2.77) earnings per share over the last year. Bicycle Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 6th, 2021 based off prior year’s report dates.

IS BICYCLE THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:BCYC)

4 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Bicycle Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Bicycle Therapeutics stock.
Bicycle Therapeutics

ASTRONOVA EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:ALOT)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN ASTRONOVA? (NASDAQ:ALOT)

Wall Street analysts have given AstroNova a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstroNova wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.

BEADELL RESOURCES EARNINGS ESTIMATES AND ACTUALS BY QUARTER (ASX:BDR)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN BEADELL RESOURCES? (ASX:BDR)

Wall Street analysts have given Beadell Resources a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Beadell Resources wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.